ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Irish pharma group ICON carried out trial of Pfizer-BioNTech vaccine
The Irish Times discusses how ICON carried out the Pfizer-BioNTech vaccine trials.
Vaccine trials were run to the highest regulatory standards
Dr. Nuala Murphy, President of Clinical Research Services, discusses how ICON carried out the COVID-19 vaccine trials.
True patient-focused research through decentralised and hybrid trials
ICON experts offer insights on the key approaches and technologies that are driving patient engagement forward.
Pharma’s digital transformation – How to best incorporate wearables amid an evolving landscape
A thought leadership piece which examines how disruptions from COVID-19 have forced sponsors, clinicians and regulators to embrace digital's full potential to keep clinical trials moving forward.
Pfizer COVID vaccine trial proved remote monitoring, other innovations work, ICON CEO says
ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post- pandemic.
Advancing digital endpoints in clinical trials
Marie McCarthy and Manpreet Sidhu discuss some of the challenges associated with the widespread adoption of digital health technology, the data that can be leveraged from wearables, and where advances are being made.
Life Sciences special feature
ICON recently contributed to the Irish Times' Life Sciences special feature with expert commentary from Dr. Nuala Murphy, President of Clinical Research Services, a case study with CFO Brendan Brennan, and a report on career opportunities for clinical researchers with a job profile of Rory Considine, Clinical Operations Manager.
Rediscovering HIV: A new decade of research and innovation on the horizon
In this Pharmafile article, Dr. Caroline Forkin and Shelley McLendon discuss a new decade of research and innovation on the horizon for HIV.
UK regulator defends rapid approval of vaccine after Fauci criticism
ICON’s Dr. Andrew Garrett, Executive Vice President Scientific Operations, comments on MHRA, the UK regulator, following their emergency use authorisation of the Pfizer COVID-19 vaccine.
Decentralised & hybrid trials: The future of clinical trials post pandemic
An interview with EB McLindon on why the future of drug development involves decentralising parts of the clinical trial process.